Cereno Scientific Launches Phase I Study of CS014 for PH-ILD Treatment After FDA Approval

Cereno Scientific, a pioneering biotech firm based in Gothenburg, Sweden, has announced the initiation of a Phase I pharmacokinetic study of its promising drug candidate, CS014, following regulatory approval from the Swedish Medical Products Agency. This pivotal study aims to streamline the development pathway for CS014, which is being investigated as a treatment option for pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Background on CS014 Development

CS014 is an innovative histone deacetylase (HDAC) inhibitor, meticulously designed to modulate epigenetic pathways that drive cardiovascular and pulmonary diseases. The decision to advance to a Phase I study comes after positive feedback from a pre-investigational new drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA), which indicated that the pharmacokinetic data from this study would support the next phase of clinical trials without the need for additional safety evaluations.

The Phase I study will comprise an open-label, randomized, two-period crossover trial involving 14 healthy adult volunteers. Participants will undergo seven days of repeat oral dosing of CS014, which will be compared with valproic acid (VPA), a well-established HDAC inhibitor. The main aim is to characterize both total and unbound plasma concentrations of CS014, establishing its pharmacokinetic profile at steady state in comparison to VPA.

Significance of the Phase I Study

This study marks a strategic and regulatory-aligned advancement for Cereno Scientific. CEO Sten R. Sörensen commented, "By incorporating FDA feedback early, we have developed a targeted pharmacokinetic program that supports our path toward a Phase IIb study in PH-ILD." The streamlined protocol is expected to enable a more capital-efficient approach to bringing new treatments to market, potentially accelerating the timeline for patient access to CS014.

The regulatory clarity gained from the FDA’s approval is crucial for the planned progression towards a Phase II trial in Q1 2027. Successful outcomes from the Phase I study could eliminate the requirement for extensive nonclinical safety studies or a Phase IIa trial, allowing Cereno to focus on the pivotal Phase IIb preparations without delay.

The Science Behind CS014

CS014 represents the next generation of HDAC inhibitors, part of Cereno Scientific's differentiated platform targeting multiple mechanisms involved in the pathology of cardiopulmonary diseases. With its innovative design, CS014 aims to tackle key pathological processes, including vascular remodeling, fibrosis, inflammation, and thrombosis.

CMO Rahul Agrawal emphasized, "CS014 builds on our significant expertise in HDAC inhibition and epigenetic modulation. By generating comparative pharmacokinetic data with VPA, we can advance CS014 while leveraging the extensive clinical history of this HDAC inhibitor class." This approach not only clarifies the drug’s potential therapeutic profile but also provides confidence in its safety and ease of administration.

Future Prospects

Data from the Phase I pharmacokinetic study is anticipated in mid-2026, serving as a cornerstone for future development and regulatory submissions. Cereno Scientific is driven by its mission to provide innovative, life-enhancing therapies for patients with rare cardiovascular and pulmonary conditions. With CS014, they are poised to pave the way for new treatment avenues in areas of significant unmet medical need.

As Cereno continues to push the boundaries of biopharmaceutical innovation, the success of CS014 could emerge as a beacon of hope for patients grappling with the challenges of PH-ILD, ultimately supporting better quality of life and health outcomes for those in need.

For additional information and updates on the study’s progress and future developments, interested parties are encouraged to stay connected with Cereno Scientific through their official website and press releases.